CAPR — Q2 2026 Financial Report Analysis

Spending for a launch the FDA hasn't approved yet

Capricor Therapeutics had no revenue in the second quarter of 2026, which is normal for a company whose only late-stage product, the Duchenne muscular dystrophy (DMD) cell therapy Deramiocel, is still under FDA review. What changed is how fast it is spending. The net loss widened to $40.7 million from $25.9 million a year earlier, because Capricor is already hiring, building manufacturing space and paying legal and consulting bills as if approval were coming. The regulatory picture got harder over the same months. An FDA advisory committee voted 9–3 against the heart-function claim on July 29, a statistical correction weakened the trial's main heart result, and on August 24 (after this 10-Q was filed) the FDA pushed its decision date from August 22 to November 22, 2026.

At a glance

• Operating expenses rose 55% to $42.9 million. Administrative costs more than doubled (+148%), mostly lawyers and consultants for "regulatory and pre-commercial initiatives." That is launch spending, booked before there is anything to sell.
• Cash and investments fell from $318.1 million to $237.9 million in six months. That is about $80 million gone, or roughly 18 months of runway at the first-half pace. The pace is still rising.
• Lease liabilities jumped from $14.5 million to $91.0 million after Capricor signed a 171,000 sq ft San Diego headquarters and manufacturing lease. Either side can cancel it if Deramiocel isn't approved by December 31, 2026.

The quarter in numbers

A company with no revenue has no operating margin, so this table tracks what matters for a pre-revenue biotech: how much it spends and how much cash it has left.

The net loss for the first six months was $74.7 million, against $50.3 million a year earlier. Q2 alone cost about $6.8 million more than Q1, whose loss was $33.9 million (the $74.7 million half-year loss minus Q2's $40.7 million).

Where the money went

Research and development (+$6.8M, +31%). The filing breaks the increase into four parts:

• Deramiocel program costs (+$3.2M). The program cost $13.1 million, up from $9.8 million, mostly for "expanded manufacturing production, and commercial-related expenses for Deramiocel in preparation for potential commercial launch."
• Staff costs (+$2.1M). More employees.
• Stock-based pay (+$1.3M).
• Facilities (+$0.6M).

Spending on the exosome research platform fell to $0.5 million from $1.2 million. Management says it is "minimizing expenses related to the exosome platform until further regulatory clarity is obtained." In other words, the company is putting nearly all of its money into Deramiocel.

General and administrative (+$8.4M, +148%). Professional services drove more than half of the increase (+$4.1M). The filing attributes it to "increased legal and consulting costs related to our continuing regulatory and pre-commercial initiatives." That covers a lot of activity in this period:

• Capricor sued its US distribution partner, Nippon Shinyaku (NS), in May.
• It received a shareholder litigation demand.
• Mesoblast filed a patent suit against it in July.

The rest of the increase came from facilities (+$1.4M), staff (+$1.0M), stock-based pay (+$1.1M) and other pre-commercial costs (+$0.8M).

What the headline numbers hide

• The cash burn is worse than the net loss suggests, and it is rising. The net loss includes $12.0 million of stock-based pay, which costs no cash. Without it, operating cash outflow was $60.7 million in the first half, or 81% of the net loss. But Capricor also spent $16.6 million on equipment, leasehold improvements and construction, up from $2.6 million a year earlier. It also repaid a $6.3 million state grant (CIRM) that had converted into a loan ($3.4 million of principal plus $2.9 million of accrued interest). Together, the cash pile fell by $80.2 million in six months.
• Last year's cash flow had a one-off boost. In the first half of 2025, Capricor collected $10.3 million of receivables. Management names this as part of the $34.1 million year-over-year jump in operating cash outflow. It is not a recurring item, so part of the increase is a comparison effect, not new spending.
• The cash didn't really drop to $20.9 million. Cash and cash equivalents fell from $287.8 million to $20.9 million because Capricor moved about $187 million into marketable securities (short-term investments it can sell quickly). The true decline is the $80.2 million in the combined total.
• Most of the $91 million lease liability depends on approval. Capricor recorded a $76.3 million right-of-use asset for the new Towne Centre Drive lease. A right-of-use asset is the accounting value of the right to occupy a building. Capricor booked it as though the lease starts August 22, 2026, the old decision date. But the lease only formally begins at FDA approval or on December 31, 2026, whichever comes first. Either party can terminate it if Deramiocel isn't approved by year-end, and that deadline is now only about five weeks after the new November 22 decision date. The landlord is also offering a tenant-improvement allowance of up to $31.6 million (money toward building out the space), which Capricor must repay if the lease never starts. The allowance had not been drawn at June 30.
• Per-share losses look milder because the share count grew. Weighted shares rose 27% to 57.9 million because of shares issued during 2025. Those included 2.7 million shares sold through an at-the-market (ATM) program, which sells new shares gradually on the open market, for about $77.5 million. So the loss grew 57% but the loss per share grew only 23%. No shares were sold in 2026 through the filing date. The ATM program is still open, and the stock price after the FDA decision will decide how expensive any new money is.
• Revenue recognition is not an issue here. The $12.0 million Japan upfront payment from NS remains deferred, meaning cash received but not yet counted as revenue. It has been unchanged since year-end.

The regulatory story behind the numbers

This report covers spending, but the stock price will depend on the FDA. The 10-Q describes four setbacks since the spring:

1. The heart result weakened. In the HOPE-3 Phase 3 trial, the key secondary endpoint was left ventricular ejection fraction (LVEF), which measures how much blood the heart pumps with each beat. After Capricor corrected its statistical model, the LVEF result went from p=0.04 to p=0.09. A p-value of 0.04 cleared the usual 0.05 bar for a real effect; 0.09 does not. The treatment difference also shrank from 2.4 to 1.8 percentage points. Because of the trial's testing order, every endpoint tested after LVEF is now only "nominal" (exploratory).
2. The primary endpoint still holds. The trial's main goal was slower loss of arm and hand function, measured on the PUL 2.0 scale. That result was unaffected: a 4.55 percentage-point difference in favor of Deramiocel, p=0.029.
3. The advisory panel voted against the heart claim. On July 29, the FDA's expert committee voted 9–3 against the evidence for treating DMD heart disease (cardiomyopathy). The panel did not vote on arm function, but the company describes its discussion of that endpoint as "directionally supportive."
4. An inspection found one problem. A July FDA inspection of the HOPE-3 trial's conduct ended with one observation (a "Form 483"), covering procedures, documentation and vendor oversight. Capricor says it doesn't affect data integrity and has responded.

Capricor responded by narrowing its request. It filed a BLA amendment that adds 24-month follow-up data and asks for a label focused on upper-limb function. (The BLA, or Biologics License Application, is the application to sell the therapy.) The FDA classified the amendment as major, which moved the decision to November 22.

Takeaway: Capricor is spending as if Deramiocel will be approved. Administrative costs are up 148%, it has signed a lease worth about $76 million in present value, and capital spending rose more than six-fold. Meanwhile, the case for approval has narrowed to one endpoint, arm function at p=0.029, after the heart claim lost an FDA panel vote 9–3. The $237.9 million cushion covers this spending for now. The risk is that a rejection or another delay past December 31 would leave a cost base and a facility commitment built for a launch that doesn't happen.

Outlook

Management gives no financial guidance. It says it will provide "additional guidance on its longer-term financial outlook" for Deramiocel "following greater regulatory clarity." It also says current funds cover operations for at least 12 months from the filing. Dates to watch:

• November 22, 2026: the FDA decision date. An approval limited to upper-limb function is the most plausible positive outcome given the panel vote. Even then, how the label is worded will matter for how many patients qualify.
• December 31, 2026: lease termination right. If approval slips past year-end, either side can walk away from the Towne Centre lease, and up to $76 million of right-of-use asset and matching liability would come off the balance sheet.
• Arbitration with Nippon Shinyaku, expected "this fall." Capricor wants to undo the US distribution deal, arguing its pricing structure is "fundamentally flawed." The outcome decides whether Capricor launches Deramiocel itself (more cost, more revenue) or through NS (milestone and revenue-share payments).
• Mesoblast patent suit, filed July 16 in Delaware. It seeks an injunction (a court order to stop) and damages. It is early, but it adds legal cost and some launch risk.
• NIAID's final COVID vaccine results, expected later in 2026. These come from a government-run Phase 1 trial of Capricor's exosome-based vaccine. They matter for the exosome platform, though not for the near-term numbers.

Our read: expect quarterly spending of $40–45 million to continue through the FDA decision. If Deramiocel is approved, spending will rise further as launch costs grow and Capricor will probably raise capital. If it is rejected, look for quick cuts to G&A and the facility build-out, and a test of whether the year-end lease exit gets used.